This recombinant monoclonal antibody is a rhesusized version of the anti–interleukin-10 (IL-10), based on the clone 1F11, was engineered to express rhesus macaque IgG1 constant regions with L234A and L235A (“LALA”) mutations that abrogate Fcγ receptor binding, eliminating effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement activation. The variable regions have been CDR-grafted for optimal compatibility with rhesus immunoglobulin frameworks, minimizing immunogenicity in in vivo studies using nonhuman primates (NHPs).

The anti-IL-10 antibody selectively binds to and neutralizes the IL-10 cytokine, blocking its immunosuppressive function without targeting the IL-10 receptor. This distinction is critical in experimental paradigms where direct cytokine blockade is preferred for dissecting IL–10–mediated signaling and downstream effects on immune regulation, inflammation, and tolerance.

Key Features and Advantages
    •    Rhesusized IgG1 format for compatibility in NHP models, reducing anti-drug antibody (ADA) responses.
    •    Fc-silent LALA mutation eliminates effector function, enabling clean mechanistic studies of cytokine activity without off-target FcγR engagement.
    •    Specific for IL-10 ligand, not receptor, allowing selective cytokine neutralization.
    •    Recombinant production ensures lot-to-lot consistency and high purity.
    •    Suitable for in vitro or in vivo applications in rhesus macaques.

Recommended Applications
    •    Cytokine neutralization assays in rhesus PBMC or tissue culture systems.
    •    In vivo blockade of IL-10 in NHP models.
    •    Mechanistic studies of IL-10 function in immune homeostasis and regulation.